Você está deixando o Portal Médico GSK

Você está prestes a deixar o site da GSK. Ao clicar neste link, você será direcionado a um site que não pertence ou é controlado pela GSK. Portanto, a GSK não é responsável por demais conteúdos presentes neste site.

Continuar

Voltar

HIV: coinfecção com tuberculose - Caso clínico

Assista aos comentários sobre um caso clínico de tuberculose associada ao HIV.

Video player requires JavaScript enabled. You can download this video here: https://edgesuite.gskstatic.com/HealthSites/Health/Brazil/MP4/Portal_Medico/20181106_highlights_GLASGOW2018_HIV_TUBERCULOSE-BR-HIVP-0111-18.mp4

   

  • Referências

    *No estudo NIX-TB foram avaliados 75 indivíduos, sendo 38 pessoas vivendo com HIV. Dessas, 33 (89%) responderam de forma favorável ao tratamento para TB.

    1. DOOLEY, KE. et al.  Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr; 62(1):21-7, 2013.

    2. DOOLEY, KE. et al. INSPIRING: Safety and efficacy of dolutegravir-based 
    ART in TB/HIV co-infected adults at week 48. In: 22nd International AIDS Conference, Amsterdam, Netherlands, July 23-27, 2018. Slides TUAB0206. Disponível em: <http://www.natap.org/2018/IAC/IAC_29.htm>. Acesso em: 01 nov. 2018.

    3. MEINTJES, G. HIV-associated tuberculosis: diagnosis, management and prevention. Oral abstract O321. Journal of the International AIDS Society; 21(S8):e25187, 2018.

    4. WORLD HEALTH ORGANIZATION (WHO). HIV-Associated Tuberculosis. Disponível em: <https://www.who.int/tb/areas-of-work/tb-hiv/tbhiv_factsheet.pdf?ua=1>. Acesso em: 01 nov. 2018.

    5. GUPTA-WRIGHT, A. Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicenter, parallel-group, double-blind, randomised controlled trial. Lancet; 392(10144):292-301, 2018.

    6. CONRADIE, F. et al. Sustained high rate of successful treatment outcomes: Interim  results of 75 patients in the Nix-TB clinical study of pretomanid, bedaquiline  and  linezolid. In: TB Alliance. 25 October 2018, The Hague, Netherlands. Disponível em: <https://www.dropbox.com/s/gu8l27grq38psul/Nix%20TB%20interim%20results%20-%2010-25-18.pdf?dl=0>. Acesso em: 04 nov. 2018.

    7. BRASIL. Ministério da Saúde.  Protocolo Clínico e Diretrizes Terapêuticas para Manejo da Infecção pelo HIV em Adultos. Disponível em: <http://www.aids.gov.br/system/tdf/pub/2013/64484/pcdt_adulto_29_08_2018_webb.pdf?file=1&type=node&id=64484&force=1>. Acesso em: 04 nov. 2018.

    8. GRINSZTEJN, B. et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis; 14(6):459-67, 2014.

    9. MEINTJES, G. et al. Randomized controlled trial of prednisone for prevention of paradoxical TB-IRIS. In: CROI, 2017. Abstract 81LB. Disponível em: <http://www.croiconference.org/sessions/randomized-controlled-trial-prednisone-prevention-paradoxical-tb-iris>. Acesso em: 04 nov. 2018.

    10. EUROPEAN AIDS CLINICAL SOCIETY (EACS). Guidelines. Version 9.1. Disponível em: <http://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf>. Acesso em: 30 out. 2018.

    11. DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Disponível em: <https://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf>. Acesso em: 30 out. 2018.

    12. WASSERMAN, S. et MEINTJES, G. The diagnosis, management and prevention of HIV-associated tuberculosis. S Afr Med J; 104(12):886-93, 2014.